Guy G Brusselle
Overview
Explore the profile of Guy G Brusselle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
216
Citations
8849
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bogaert B, Debisschop A, Ehouarne T, Van Eeckhoutte H, De Volder J, Jacobs A, et al.
Nano Lett
. 2024 Mar;
24(10):2961-2971.
PMID: 38477058
The delivery of RNA across biological barriers can be achieved by encapsulation in lipid nanoparticles (LNPs). Cationic amphiphilic drugs (CADs) are pharmacologically diverse compounds with ionizable lipid-like features. In this...
12.
Markus A, Rijnbeek P, Kors J, Burn E, Duarte-Salles T, Haug M, et al.
BMJ Open Respir Res
. 2024 Feb;
11(1).
PMID: 38413124
Background: There is a lack of knowledge on how patients with asthma or chronic obstructive pulmonary disease (COPD) are globally treated in the real world, especially with regard to the...
13.
Lu T, Lahousse L, Wijnant S, Chen J, Brusselle G, van Hoek M, et al.
Respir Res
. 2024 Feb;
25(1):85.
PMID: 38336742
Background: Chronic obstructive pulmonary disease (COPD) and asthma associate with high morbidity and mortality. High levels of advanced glycation end products (AGEs) were found in tissue and plasma of COPD...
14.
Bertels X, Ross J, Faner R, Cho M, Ikram M, Brusselle G, et al.
ERJ Open Res
. 2024 Feb;
10(1).
PMID: 38333649
Background: The determinants and health outcomes of lung function trajectories in adults among the general population are poorly understood. We aimed to identify and characterise clusters of lung function trajectories...
15.
Higbee D, Lirio A, Hamilton F, Granell R, Wyss A, London S, et al.
Eur Respir J
. 2023 Dec;
63(1).
PMID: 38097206
Background: Preserved ratio impaired spirometry (PRISm) is defined as a forced expiratory volume in 1 s (FEV) <80% predicted and FEV/forced vital capacity ≥0.70. PRISm is associated with respiratory symptoms...
16.
Lommatzsch M, Buhl R, Canonica G, Ribas C, Nagase H, Brusselle G, et al.
Lancet Respir Med
. 2023 Dec;
12(2):96-99.
PMID: 38071999
No abstract available.
17.
Pera V, Brusselle G, Riemann S, Kors J, van Mulligen E, Parry R, et al.
Front Pharmacol
. 2023 Nov;
14:1276340.
PMID: 38035014
Monoclonal antibodies (mAbs) targeting immunoglobulin E (IgE) [omalizumab], type 2 (T2) cytokine interleukin (IL) 5 [mepolizumab, reslizumab], IL-4 Receptor (R) α [dupilumab], and IL-5R [benralizumab]), improve quality of life in...
18.
Bertels X, Edris A, Garcia-Aymerich J, Faner R, Meteran H, Sigsgaard T, et al.
BMJ Open Respir Res
. 2023 Aug;
10(1).
PMID: 37612099
Background: The prevalence and clinical profile of asthma with airflow obstruction (AO) remain uncertain. We aimed to phenotype AO in population- and clinic-based cohorts. Methods: This cross-sectional multicohort study included...
19.
Lommatzsch M, Brusselle G, Levy M, Canonica G, Pavord I, Schatz M, et al.
Lancet Respir Med
. 2023 Jan;
11(6):573-576.
PMID: 36716752
The management of asthma has changed fundamentally during the past two decades. Precise assessment and phenotyping are now required to establish individually targeted treatment with disease-modifying anti-asthmatic drugs (DMAADs). Patients...
20.
Van Eeckhoutte H, Donovan C, Kim R, Conlon T, Ansari M, Khan H, et al.
Eur Respir J
. 2022 Dec;
61(4).
PMID: 36549711
Background: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of regulated cell death (including apoptosis and necroptosis) and inflammation, both drivers of COPD pathogenesis. We aimed to define the...